The Effects of MK-0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture-Reference-Cited by-同舟云学术

The Effects of MK-0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture

Published:2004-04 Issue:4 Volume:52 Page:516-523
ISSN:0002-8614
Container-title:Journal of the American Geriatrics Society
language:en
Short-container-title:

Author:

Bach Mark A.,Rockwood Kenneth,Zetterberg Carl,Thamsborg Gorm,HÃ©bert RÃ©jean,Devogelaer Jean-Pierre,Christiansen Jens Sandahl,Rizzoli RenÃ©,Ochsner J.Lockwood,Beisaw Norman,Gluck Oscar,Yu Leisure,Schwab Thomas,Farrington Jeanne,Taylor Alice M.,Ng Jennifer,Fuh Vivian,

Publisher

Wiley

Subject

Geriatrics and Gerontology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1532-5415.2004.52156.x/fullpdf

Reference43 articles.

1. Hip fracture in the elderly;Ethans;Postgrad Med,1998

2. Decline in physical function following hip fracture;Marottoli;J Am Geriatr Soc,1992

3. Clinical outcomes and mortality after hip fracture;Baudois;A two-year follow-up study,1996

4. Predictors of functional recovery 1 year following hospital discharge for hip fracture;Magaziner;A prospective study,1990

5. Mortality, disability and nursing home use for persons with and without hip fracture;Leibson;A population-based study,2002

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Attenuating Cancer Cachexia-Prolonging Life;Frailty and Sarcopenia - Recent Evidence and New Perspectives;2022-10-26

2. Characterization of growth hormone secretagogue small molecule ibutamoren (MK‐0677) and its possible metabolites in thoroughbred horses for doping control;Rapid Communications in Mass Spectrometry;2022-07-19

3. Equine metabolism of the growth hormone secretagogue MK‐0677 in vitro and in urine and plasma following oral administration;Drug Testing and Analysis;2022-03-25

4. Characterization of equine liver microsome‐generated metabolites of growth hormone secretagogue small molecule ibutamoren;Rapid Communications in Mass Spectrometry;2021-10-09

5. Pharmacological Intervention for Sarcopenia in Chronic Kidney Disease;Recent Advances of Sarcopenia and Frailty in CKD;2020